Ruxolitinib in Pediatric Patients with Treatment-<i>Naïve</i> or Steroid-Refractory Acute Graft-Versus-Host Disease: Primary Findings from the Phase I/II REACH4 Study
Franco Locatelli(Bambino Gesù Children's Hospital), Cristina Díaz de Heredia(Universitat Autònoma de Barcelona), Christine Rosko(Novartis (United States)), Katsuyoshi Koh(Saitama Children's Medical Center), Maura Faraci(Istituto Giannina Gaslini), Anirudh Prahallad(Novartis (Switzerland)), Pantelia Roussou(Novartis (Switzerland)), Virginie Gandemer, Grace Cleary(Novartis (Ireland)), Hyoung Jin Kang(Seoul National University Hospital), Henrique Bittencourt(Centre Hospitalier Universitaire Sainte-Justine), Yoshiyuki Takahashi(Nagoya University), Annie St. Pierre(Novartis (Switzerland)), Bénedicte Bruno(Centre Hospitalier Universitaire de Lille), Fanny Rialland(Hôpital Mère-Enfant)
Cited by 11
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study
|The Lancet Respiratory Medicine|2020|738